Skip to main content

Table 1 Clinical features and immunotype of our patient with a STAT3 GOF mutation

From: Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation

tocilizumab therapy

before

after

lymphadenopathy

yes

no

hepatosplenomegaly

yes (severe)

mild

autoimmune pancytopenia

yes

no

myositis

worse

better

alopecia

yes

better

WBC

(×109/L)

0.90–1.36#

0.9–6.8##

4.7–8.3###

HB

g/L

87–106#

46–139##

112–139###

PLT

(×109/L)

32–51#

32–123##

107–178###

IgM

1.84

0.62

IgA

1.3

0.25

IgG

14.5

6.6 a

IgE

< 2

< 2

CD3

89.13% (607)

82.87% (786)

CD4

32.41% (221)

30.61% (290)

CD8

51.17% (349)

48.70% (462)

CD4/CD8

0.63

0.63

CD19

8.74% (60)

9.08% (31)

NK

1.49% (10)

7.28% (69)

  1. * with monthly IVIG replacement
  2. # before glucocorticoid treatment, ## after glucocorticoid treatment;
  3. ### after 1 month of tocilizumab therapy